UBS Maintains Neutral on BioNTech, Lowers Price Target to $101
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Neutral rating on BioNTech (NASDAQ:BNTX) and lowers the price target from $110 to $101.
March 27, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Eliana Merle maintains a Neutral rating on BioNTech and lowers the price target from $110 to $101.
The reduction in the price target by UBS suggests a less optimistic outlook on BioNTech's stock price in the short term, potentially leading to negative investor sentiment and a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100